Article

Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the UK B.1.1.7 and SA B.1.351 variant

2021-04-26

Abstract excerpt

SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide is effective against the D614G, B.1.1.7 and B.1.351 variants. Our data fur...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a588a629-fb76-51d1-9555-4160c1d7a1f6
DOI: 10.1101/2021.04.26.441457

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the UK B.1.1.7 and SA B.1.351 variantDOI 10.1101/2021.04.26.441457Read

Real-Life Practice of Kelleni’s Protocol in Treatment and Post Exposure Prophylaxis of SARS CoV-2 Omicron HV.1 and JN.1 SubvariantsSemantic proximity Read

The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamstersSemantic proximity Read

An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.Semantic proximity Read

Niclosamide potentiates TMEM16A and induces vasoconstrictionSemantic proximity Read

Methylene blue, Mycophenolic acid, Posaconazole, and Niclosamide inhibit SARS-CoV-2Omicron variant BA.1 infection of human airway epithelial explant culturesSemantic proximity Read

Prospects for RNAi Therapy of COVID-19Semantic proximity Read

Niclosamide inhibits the replication of highly pathogenic avian influenza A (H5Nx) viruses and antiviral-resistant mutants.Semantic proximity Read

Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in severe COVID-19Semantic proximity Read

An intranasal ASO therapeutic targeting SARS-CoV-2Semantic proximity Read

In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 TreatmentSemantic proximity Read

Niacinamide enhances cathelicidin mediated SARS-CoV-2 membrane disruptionSemantic proximity Read

Niclosamide reverses SARS-CoV-2 control of lipophagySemantic proximity Read